NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
75.62 USD   +0.99%
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société NOVOCURE LIMITED
07/28NOVOCURE : Q2 Earnings Snapshot
AQ
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
PU
07/28Novocure Reports Second Quarter 2022 Financial Results
BU
07/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
07/27Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fie..
BU
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
BU
06/10NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. o..
AQ
06/03NOVOCURE : Press Release of NovoCure Limited, dated June 3, 2022 - Form 8-K
PU
06/03NOVOCURE LTD : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
06/03Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Field..
BU
05/26NOVOCURE : Announces Clinical Collaboration with MSD on a Registrational-Intent Study to E..
PU
05/26NOVOCURE LTD : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
AQ
05/26Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to ..
BU
04/28NOVOCURE : Q1 Earnings Snapshot
AQ
04/28NOVOCURE : Quarterly net revenues of $137.5 million with 80% gross margin - Form 8-K
PU
04/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
04/28Novocure Reports First Quarter 2022 Financial Results
BU
04/19Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
BU
04/13NOVOCURE LTD : Change in Directors or Principal Officers, Financial Statements and Exhibit..
AQ
04/08Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) ..
BU
04/07NOVOCURE LTD : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/01Novocure to Report First Quarter 2022 Financial Results
BU
03/24Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survi..
BU
03/23Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 ..
BU
03/23NOVOCURE LTD : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
03/23NOVOCURE : Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 S..
PU
02/28Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technologic..
BU
02/24Novocure's General Counsel Resigns After 10 Years of Service
BU
02/24NOVOCURE : Q4 Earnings Snapshot
AQ
02/24NOVOCURE : Invested record $201 million in 2021 in research and development initiatives in..
PU
02/24New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
BU
02/24Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Compa..
BU
02/24NOVOCURE LTD MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
01/10NOVOCURE : DMC interim analysis for INNOVATE-3 pivotal trial in ovarian cancer anticipated..
PU
01/10Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provi..
BU
01/04Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
BU
2021NOVOCURE LTD : Other Events (form 8-K)
AQ
2021NOVOCURE : Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New H..
PU
2021Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New ..
BU
2021NOVOCURE LTD : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
AQ
2021Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research P..
BU
2021Novocure to Participate in Two Upcoming Investor Conferences
BU
2021Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treati..
BU
2021Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncol..
BU
20212-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblasto..
BU
2021NOVOCURE : Q3 Earnings Snapshot
AQ
2021NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2021Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update - For..
PU
2021Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
BU
2021Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor T..
BU
2021NOVOCURE : Announces 15 Presentations at the American Society for Radiation Oncology 2021 ..
BU
2021NOVOCURE : to Report Third Quarter 2021 Financial Results
BU
2021NOVOCURE : and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Trea..
BU
2021NOVOCURE : Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of T..
AQ
2021NOVOCURE : Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fi..
BU
2021NOVOCURE : FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System fo..
BU
2021NOVOCURE : to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
BU
2021NOVOCURE : Appoints Bill Burke as Chief Human Resources Officer
BU
2021NOVOCURE : Q2 Earnings Snapshot
AQ
2021NOVOCURE : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
2021NOVOCURE : Reports Second Quarter 2021 Financial Results and Provides Company Update
BU
2021NOVOCURE : Announces Recipients of 3rd Annual AACR-Novocure : Grants for Tumor Treating Fi..
BU
2021NOVOCURE : to Report Second Quarter 2021 Financial Results
BU
2021NOVOCURE : Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Tria..
BU
2021NOVOCURE : Initiates Usability Study for Flexible Torso Array
BU
2021NOVOCURE LTD : Change in Directors or Principal Officers, Submission of Matters to a Vote ..
AQ
2021NOVOCURE : Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate..
BU
2021NOVOCURE : Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tum..
BU
2021NOVOCURE : Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer ..
PU
2021NOVOCURE : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
2021NOVOCURE : Q1 Earnings Snapshot
AQ
2021NOVOCURE : Reports First Quarter 2021 Financial Results and Provides Company Update
BU
2021NOVOCURE : Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluat..
BU
2021NOVOCURE LTD : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
1  2  3  4  5Next
Upcoming event on NOVOCURE LIMITED